The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

North Texas took center stage as a global hub for innovation during Advanced Therapies Week (ATW) 2025. This signature event showcased the intersection of cutting-edge science, transformative ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the ...

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

Study reveals the impact of X chromosome on brain aging in women. Learn how maternal and paternal X chromosome can influence cognitive abilities.